CN1171896C - Syringic general saponin extractive and its prepn and medicinal composition - Google Patents
Syringic general saponin extractive and its prepn and medicinal composition Download PDFInfo
- Publication number
- CN1171896C CN1171896C CNB021332045A CN02133204A CN1171896C CN 1171896 C CN1171896 C CN 1171896C CN B021332045 A CNB021332045 A CN B021332045A CN 02133204 A CN02133204 A CN 02133204A CN 1171896 C CN1171896 C CN 1171896C
- Authority
- CN
- China
- Prior art keywords
- syringic
- time
- lilac
- general saponin
- extractive
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
- Steroid Compounds (AREA)
Abstract
The present invention relates to a lilac total saponin extract, a preparation method thereof and a medicinal composition thereof, which belongs to the field of medicine. Lilac leaves are boiled for 2 to 3 times by adding water., wherein the time length of each time is from 1 hour to 3 hours; the solutions obtained by boiling water of each time are merged and filtered, and the filtered solution is reserved; the filtered solution passes through macroporous resin and then is washed by water to approach to be colorless, the washing solution is discarded, the washed filtered solution is eluted by 50% to 88% of ethanol, and the eluent of the time is collected; the lilac total saponin extract is obtained by concentration and dryness after the ethanol is recovered by the eluent. The lilac total saponin has the characteristics of light yellow to dark orange, powdery shape and bitter taste. The content of the lilac total saponin extract accounts for 3% to 7% of the total weight of the dry lilac leaves. The medical composition containing the lilac extract as an active component is used for treating liver diseases or protect livers.
Description
Technical field
The present invention relates to obtain total saponin extracts, its preparation method and the pharmaceutical composition that contains these extracts by extracting leaf of Syringa oblata Lindl. effective constituent.
Background technology
Syringa oblata Lindl. (Syringa oblata Lindl.) is Oleaceae (Oleaceae) Genus Syringa (Syringa) machaka.Mainly be distributed in Northeast China, the Inner Mongol, North China, East China and northwest.Be born in border, roadside, how by artificial culture.Among the people this leaf is used as medicine, is mainly used in antisepsis and anti-inflammation, antiviral and hepatic cholagogic etc.Indicate and contain the biologically active substance of preventing and treating above-mentioned disease in this platymiscium, study its chemical ingredients and biological activity and have broad prospects.External scientist has done a large amount of research work to leaf, flower, bark and the form layers of genus syringa ocean cloves, isolate nearly hundred kinds of chemical ingredientss, wherein many have a pharmacologically active, they mostly exist with the form of glycosides, can be divided into by the chemical structure type of its aglycon: the plain phenols of phenylpropyl alcohol, iridoids, flavonoid and phenylethanol etc.China medicine worker furthers investigate the pharmacologically active of Syringa oblata Lindl. in recent years, and the result shows that Syringa oblata Lindl. has antisepsis and anti-inflammation, antiviral, step-down, brings down a fever, kobadrin and effect such as protect the liver.Wherein, hepatic cholagogic acts on the record that " Changbai Mountain plant amedica will " has Syringa oblata Lindl. " to control hepatitis ", the history of the among the people also useful Syringa oblata Lindl. of China, daphne lilac treatment hepatitis.The former Norman Bethune Medical University first clinical hospital makes tablet in treatment acute icterohepatitis curative ratio with the medicinal extract of root of Velvety Lilac and leaf of Syringa oblata Lindl. and reaches 93.7%.Syringopicroside in the Syringa oblata Lindl. has stronger choleretic effect.
Summary of the invention
The invention provides a kind of Syringic general saponin extractive, its preparation method comprises the steps:
One, leaf of Syringa oblata Lindl. is added poach 2～3 times, each 1～3 hour;
Two, the solution with each time poach gained merges, and filters filtrate for later use;
Three, above-mentioned filtrate is crossed macroporous adsorbent resin, wash with water then,, discard washing lotion,, collect this time elutriant with 50%～88% ethanol elution near colourless;
Four, with behind this elutriant recovery ethanol, concentrate, drying gets Syringic general saponin extractive.
It is characterized by faint yellow to darkorange, Powdered, bitter, with methyl alcohol is that the UV spectrum that solvent is tested has absorption peak in 210 nanometers, 230 nanometers, 280 nanometers, wherein 210 nanometers are maximum absorption, high performance liquid chromatography demonstrates the peak more than 10, and the content of this Syringic general saponin extractive is to account for 3%～7% of Syringa oblata Lindl. cured leaf gross weight
The invention still further relates to and contain the pharmaceutical composition of Syringic general saponin extractive, specifically, the present invention relates to contain the pharmaceutical composition that is used for the treatment of hepatopathy or protects the liver of this extract as activeconstituents.
Product of the present invention or extract can be mixed with tablet, soft or glutoid capsule by suitable mode, be used to prepare the ready to use solution that adapts with its solubleness or the granulated powders of liquid.The dosage of Syringic general saponin extractive of the present invention can be administered once or repeatedly in the scope of 30mg～500mg every day, preferred 200mg, and be administered twice every day, and suitable form of administration is an oral dosage form.
Characteristics of the present invention and beneficial effect are: Syringic general saponin extractive as the new medicinal part of Syringa oblata Lindl. in treatment hepatopathy or the drug regimen that protects the liver, effect obviously, toxic side effect is little, the curative ratio height; The aboundresources of leaf of Syringa oblata Lindl., the preparation method that the present invention adopts, simple, be fit to suitability for industrialized production, the yield height of total saponins has broad application prospects.
Description of drawings
Fig. 1, for taking the high-efficient liquid phase chromatogram of the resultant total saponin extracts of preparation method of the present invention, moving phase: methyl alcohol: water, 3.5: 6.5, C
18Post, 150mm * 4.6mm; Detect wavelength 210 nanometers.
Fig. 2, Syringic general saponin extractive are to the influence of liver injury mouse SGPT;
Fig. 3, Syringic general saponin extractive are to the influence of liver injury mouse LDH.
Embodiment
Embodiment one:
One, with leaf of Syringa oblata Lindl. dry weight 2kg, add poach 3 times, be respectively and for the first time add water 60kg, boiled 3 hours, add water 30kg for the second time and boiled 2 hours, add water 30kg for the third time and boiled 2 hours;
Two, the solution with each time poach gained merges, and filters filtrate for later use;
Three, above-mentioned filtrate is crossed macroporous adsorbent resin D
101, wash with water then, near colourless, discard washing lotion, with 55% ethanol elution, collect this time elutriant;
Four, with behind this elutriant recovery ethanol, concentrate, drying gets Syringic general saponin extractive 140g.
Embodiment two
One, with leaf of Syringa oblata Lindl. dry weight 2kg, add poach 3 times, be respectively and for the first time add water 60kg, boiled 3 hours, add water 30kg for the second time and boiled 2 hours, add water 30kg for the third time and boiled 2 hours;
Two, the solution with each time poach gained merges, and filters filtrate for later use;
Three, above-mentioned filtrate is crossed macroporous adsorbent resin D
4020, wash with water then, near colourless, discard washing lotion, with 75% ethanol elution, collect this time elutriant;
Four, with behind this elutriant recovery ethanol, concentrate, drying gets Syringic general saponin extractive 120g.
Fig. 1 is the extract obtained high-efficient liquid phase chromatogram of present embodiment two.
Embodiment three
One, with leaf of Syringa oblata Lindl. dry weight 2kg, add poach 3 times, be respectively and for the first time add water 60kg, boiled 2 hours, add water 30kg for the second time and boiled 2 hours, add water 30kg for the third time and boiled 2 hours;
Two, the solution with each time poach gained merges, and filters filtrate for later use;
Three, above-mentioned filtrate is crossed macroporous adsorbent resin AB-8, wash with water then,, discard washing lotion,, collect this time elutriant with 88% ethanol elution near colourless;
Four, with behind this elutriant recovery ethanol, concentrate, drying gets Syringic general saponin extractive 100g.
Experimental example: pharmacologically active experiment---tetracol phenixin is caused the experiment of experimental liver injury influence
(1) laboratory animal
50 of Kunming mouses, male and female half and half, body weight 19g～21g.Supply with conformity certification number by laboratory animal portion of Jilin University: the moving word 10-5107 of doctor.
(2) medicine and reagent
Tetracol phenixin (10%), Biphenylylmethylcarbinol (2%), picric acid solution
Syringic general saponin extractive
(3) experimental technique
50 of Kunming mouses, body weight 20g～23g male and female half and half is divided into 5 groups at random, 10 every group.Normal control group, CCl
4(0.01ml/10g) model group, CCl
4+ Biphenylylmethylcarbinol (2mg/10g) group, CCl
4+ Syringic general saponin extractive (2.5,10mg/10g) two dosage groups.First day abdominal injection CCl
4After respectively organize gastric infusion, second day beginning each treated animal gastric infusion of every morning once, continuously gastric infusion is 4 days, puts to death animal in one hour after administration the last day, gets blood, surveys SGPT and LDH value.
4 experimental results
The result shows: the SGPT value of liver injury group mouse is apparently higher than the normal control group, and the experiment medicine has the SGPT of reduction value trend, and the reduction trend of heavy dose of group is obvious; The LDH value of liver injury group mouse is starkly lower than the normal control group, and the heavy dose of group of experiment medicine has rising LDH value trend.Experimental result sees Table 1 and Fig. 2, Fig. 3:
Table 1 Syringic general saponin extractive is to CCl
4Cause the mouse liver injury provide protection
Normal microhepatia damage mouse
The heavy dose of group of mouse contrast model group Biphenylylmethylcarbinol small dose group
Group (n=5) is (n=6) (n=6) (n=5) (n=7)
SGPT± 52.0± 80.17± 57.67± 58.17± 69.33±
SD 10.60 11.86 7.55** 8.93** 6.44
LDH±SD 1212.3 849.1± 1177.7± 1101.9± 1090.4±
±46.1 93.8 113.3** 86.4** 265.5*
Compare * p＜0.05 * * p＜0.01 with model group
Claims (5)
1, a kind of Syringic general saponin extractive, it is characterized by faint yellow to darkorange, Powdered, bitter, with methyl alcohol is that the UV spectrum that solvent is tested has absorption peak in 210 nanometers, 230 nanometers, 280 nanometers, and wherein 210 nanometers are maximum absorption, and high performance liquid chromatography demonstrates the peak more than 10, the content of this Syringic general saponin extractive is to account for 3%～7% of Syringa oblata Lindl. cured leaf gross weight, and this Syringic general saponin is carried thing and followed these steps to obtain:
One, leaf of Syringa oblata Lindl. is added poach 2～3 times, each 1～3 hour;
Two, the solution with each time poach gained merges, and filters filtrate for later use;
Three, above-mentioned filtrate is crossed macroporous adsorbent resin, wash with water then,, discard washing lotion,, collect this time elutriant with 50%～88% ethanol elution near colourless;
Four, with behind this elutriant recovery ethanol, concentrate drying.
2, a kind of preparation method of Syringic general saponin extractive is characterized in that comprising the steps:
One, leaf of Syringa oblata Lindl. is added poach 2～3 times, each 1～3 hour;
Two, the solution with each time poach gained merges, and filters filtrate for later use;
Three, above-mentioned filtrate is crossed macroporous adsorbent resin, wash with water then,, discard washing lotion,, collect this time elutriant with 50%～88% ethanol elution near colourless;
Four, with behind this elutriant recovery ethanol, concentrate, drying gets Syringic general saponin extractive.
3, the preparation method of Syringic general saponin extractive according to claim 2 is characterized in that: macroporous adsorbent resin can adopt D
4020, D
101Or AB-8 type.
4, a kind of pharmaceutical composition contains the described Syringic general saponin extractive of claim 1 as activeconstituents.
5, pharmaceutical composition according to claim 4 is characterized in that: be used for the treatment of hepatopathy or protect the liver.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021332045A CN1171896C (en) | 2002-10-17 | 2002-10-17 | Syringic general saponin extractive and its prepn and medicinal composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021332045A CN1171896C (en) | 2002-10-17 | 2002-10-17 | Syringic general saponin extractive and its prepn and medicinal composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1403466A CN1403466A (en) | 2003-03-19 |
| CN1171896C true CN1171896C (en) | 2004-10-20 |
Family
ID=4747092
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB021332045A Expired - Fee Related CN1171896C (en) | 2002-10-17 | 2002-10-17 | Syringic general saponin extractive and its prepn and medicinal composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1171896C (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100457091C (en) * | 2003-12-30 | 2009-02-04 | 修正药业集团股份有限公司 | Dripping pills of clove leaf and its preparation process |
| EP1736167B1 (en) * | 2005-06-20 | 2018-03-21 | I.R.B. Istituto Di Ricerche Biotecnologiche S.r.l. | Extracts obtained from cell line cultures from Syringa vulgaris IRB-SV25/B (DMS:16857), their preparation and use |
| CN101780126B (en) * | 2010-03-18 | 2012-05-02 | 河南科技大学 | Ginsenoside compound in syringa pubescens turca and extraction method and application thereof |
| CN102475711B (en) * | 2010-11-30 | 2013-11-13 | 李永吉 | Novel application of syringopicroside in preparation of medicines |
-
2002
- 2002-10-17 CN CNB021332045A patent/CN1171896C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1403466A (en) | 2003-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103816296B (en) | Callicarpa total glycoside extract and preparation method and application thereof | |
| CN1398838A (en) | Diphenylethylene compound and its prepn and application in preventing and treating diabetes | |
| CN101214270B (en) | Acanthopanax senticosus effective fraction extract, preparation and application thereof | |
| CN1742763A (en) | Use of Wucenglong extract in preparing health-care product and medicines | |
| CN1706397B (en) | Composition of paeoniflorin and peony lactone glycoside with function of increasing leukocyte | |
| CN1171896C (en) | Syringic general saponin extractive and its prepn and medicinal composition | |
| CN1861104B (en) | Inula flower extractive used to breat diabets mellitus and hyperlipidemia | |
| CN1799564A (en) | Application of valeriana wallichii and its extract in preparation of medicine for treating anxiety neurosis | |
| CN101537052A (en) | Hubei caval vine general flavone extract as well as preparation method and application thereof | |
| CN101028322A (en) | Use of Maoliefengdou extract for preparing anti-cancer medicine | |
| CN1470513A (en) | Total alkaloid with anticancer activity and its formulation | |
| CN1771977A (en) | Notoginseng glycol-saponin composition and its prepn and use | |
| CN100335073C (en) | Process for preparing semen momordicae seed extract containing triterpene saponin component | |
| Nigam et al. | Pharmacognostic study, characterization of marker compounds and pharmacological review of aerial parts of hygrophila auriculata (schumach.) heine | |
| CN101658542B (en) | Soft-lithospermum total phenolic acid and use thereof in pharmacy | |
| CN100584345C (en) | Distillage of Ardisia chinensis Benth of possessing function of antivirus, extraction method and application | |
| CN1181832C (en) | Preparation of AIDS resisting medicine from indian stringbush root extract | |
| CN107485615A (en) | Purposes of the Ligustrum robust glycosides C and combinations thereof in treatment hyperlipidemia and slimming medicine is prepared | |
| Abuh et al. | Hypoglycaemic activity of Anthocleista vogelii (Planch) aqueous extract in rodents | |
| Niranjan et al. | Pharmacological investigation of leaves of polypodium decumanum for antidiabetic activity | |
| CN1434042A (en) | Cattail pollen extract and preparation process and use thereof | |
| CN1475222A (en) | Vine leaf extract and its preparation process | |
| CN116509921B (en) | Application of rice flower sesterterpene extract K01 in preparation of medicines for treating sepsis | |
| CN1628754A (en) | Local externally applied itch stopping garlic paint | |
| CN1490014A (en) | Mangiferin preparation and production thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |